The selection of Novamind's Cedar Clinical Research for this significant study reflects its deep experience hosting phase I to phase IV clinical trials, many of them focused on psychedelic medicines, and emerging therapies in neuropsychiatry. This exciting research opportunity with Merck exemplifies a growing pipeline of opportunities for us to provide contract research services to leading drug developers." "CCR has unique expertise conducting clinical trials and research studies in neuropsychiatry, for a variety of sponsors. Reid Robison, Chief Medical Officer of Novamind and Principal Investigator at CCR. "We're proud to partner with Merck and support its innovative neuroscience work to develop a potential new drug for treatment-resistant depression," said Dr.
#Novamind coupon trial
The study is titled "A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression." The clinical trial begins enrolling individuals in March 2021. The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder 1.
TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly-owned subsidiary, Cedar Clinical Research ("CCR") has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co., ("Merck"), a world-leading pharmaceutical company. Novamind's subsidiary, Cedar Clinical Research, to serve as a key clinical research site
0 kommentar(er)
